X0206 3 2018-09-13 0 0001510487 Principia Biopharma Inc. PRNB 0001751884 Gourlay Steve C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 100588 D Series B-3 Preferred Stock 0.00 Common Stock 7269 D Employee Stock Option (right to buy) 4.7236 2024-12-25 Common Stock 20035 D Employee Stock Option (right to buy) 4.9961 2025-07-20 Common Stock 5137 D Employee Stock Option (right to buy) 7.2671 2027-12-13 Common Stock 22788 D Employee Stock Option (right to buy) 9.0839 2028-04-18 Common Stock 10238 D Employee Stock Option (right to buy) 11.3549 2028-08-23 Common Stock 44033 D Warrant to Purchase Series B-3 Preferred Stock 8.9931 2022-12-29 Series B-3 Preferred Stock 625 D Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. The stock option vested and became exercisable as to 25% of the shares subject to the option on November 11, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. The stock option vested and became exercisable as to 25% of the shares subject to the option on July 21, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. The stock option will vest and become exercisable as to 25% of the shares subject to the option on December 14, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. The stock option will vest and become exercisable as to 25% of the shares subject to the option on April 19, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. The stock option will vest and become exercisable as to 25% of the shares subject to the option on August 23, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. This warrant is exercisable at any time. Steve Gourlay, by /s/ Ron Metzger, Attorney-in-Fact 2018-09-13